Mariano Viapiano, PhD
CURRENT APPOINTMENTS
LANGUAGES
RESEARCH PROGRAMS AND AFFILIATIONS
RESEARCH INTERESTS
Brain cancer therapies; tumor microenvironment; tumor invasion; extracellular matrix; nano-therapeutics; immunotherapies
EDUCATION INTERESTS
Cancer biology; cancer immunology; malignancies of the central nervous system
ASSOCIATIONS / MEMBERSHIPS
EDUCATION
PREVIOUS APPOINTMENTS
RESEARCH ABSTRACT
Brain Tumor Laboratory and Biorepository at SUNY Upstate
我们的实验室研究被称为神经胶质瘤的原发性恶性脑癌, 哪些是对常规疗法反应不佳的高侵袭性肿瘤. 我们分析和目标胶质瘤细胞与肿瘤微环境的其他成分的相互作用, 特别是神经细胞和免疫细胞，它们可以促进肿瘤的生长.
The major research focus of our lab is the extracellular matrix (ECM)，形成神经组织的支架，以及神经胶质瘤细胞在基质中引起的变化. We investigate how ECM remodeling facilitates tumor invasion, modifies the behavior of neural cells, 甚至阻止了免疫细胞对肿瘤的正常反应. Our lab currently pursues two major lines of investigation:
- Regulation of immune responses in glioma by the tumor ECM: 我们正在研究胶质瘤如何改变ECM分子的组成，以及不同的ECM成分如何调节肿瘤中免疫细胞的行为. 在这个项目中，我们也在开发新的抗ecm试剂(包括新的抗体和工程免疫细胞)，以靶向肿瘤基质，阻止肿瘤的侵袭和生长.
- Targeting the glioma-brain communication: 在这个项目中，我们研究神经胶质瘤细胞如何对神经信号作出反应并释放分子，这些分子可以协同神经元和神经胶质细胞来支持肿瘤的生长. Major research in this project is focused on: 1) targeting scaffolding/polarity proteins that are needed by glioma cells to respond to pro-tumor signals from the brain; and 2) studying ECM and neuro-endocrine factors produced by "hijacked" neural cells that support the tumor cells.
我们实验室的研究涉及各种学科和实验室技能, including molecular biology and genetics, bioinformatics, protein biochemistry, tumor stem cell culture, tumor organoids, and animal models of malignant glioma. In addition, we house the brain tumor bank of SUNY Upstate Medical University, with an extensive collection of tumor specimens, tumor cells, and patient blood, available for basic and translational research projects.我们研究的最终目标是推进新的治疗策略，以提高恶性脑肿瘤患者的生存率.
Figure 1: 用对照抗体或新型单克隆抗体(“mAb428”)治疗颅内胶质瘤.2") against the glioma-enriched ECM protein fibulin-3. Treatment with mAb428.2增加炎性巨噬细胞(IBA-1+细胞)向肿瘤核心的浸润，减缓肿瘤进展(来自Nandhu等)., Clin. Cancer Res., 2018)
Figure 2: A)来自胶质瘤干细胞的球体携带shRNA对抗支架蛋白DLG5，因为它们不能对Shh信号做出反应，所以比对照肿瘤细胞的球体生长得更小. B)当对照和DLG5敲低的胶质瘤细胞被引入新的肿瘤球体时，缺乏DLG5的胶质瘤细胞具有较低的竞争适应度并最终死亡(来自Kundu等)., Neuro-Oncology, 2022)
Recent Articles:
- Yokoda RT, Cobb WS, Yong RL, Crary JF, Viapiano MS, Walker JM，等. 在idh突变型星形细胞瘤中，CDKN2A突变与纯合缺失具有同等的预后意义. J Neuropathol Exp Neurol. (2023) PMID: 37550258
- Pramio DT, Vieceli FM, Varella-Branco E, Goes CP, Kobayashi GS, Pelegrina DV，等. CREB1结合位点启动子区域的DNA甲基化是脑特异性PKMzeta表观遗传调控的机制. Biochemica et Biophysica Acta - Gene Regulatory Mechanisms (2023) PMID: 36682583
- Moncao CC, Scrideli CA, Andrade AF, Viapiano MS, Carlotti CG, et al. 吲哚南降低儿童高级别胶质瘤细胞的活力并调节凋亡基因表达. Biomedicines (2022) PMID: 36672576
- Roshini A, Goparaju C, Kundu S, Nandhu MS, Longo SL, Longo JA, Chou J，等. 细胞外基质蛋白纤维蛋白-3/EFEMP1通过激活PI3K/Akt信号通路促进胸膜间皮瘤的生长. Front. Oncol. (2022) PMID: 36303838
- Richardson TE, Walker JM, Abdullah KG, McBrayer SK, Viapiano MS, Mussa ZS，等. Chromosomal instability in adult-type diffuse gliomas. Acta Neuropathol. Commun. (2022) PMID: 35978439
- Teixeira SA, Burim RV, Viapiano MS, Bidinotto LT, Nagashi Marie SK, Fleury Malheiros SM, Oba-Shinjo SM, Andrade AF and Carlotti CG. Alpha2beta1 integrin polymorphism in diffuse astrocytoma patients. Front. Oncol. (2022) PMID: 35936750
- 刘勇，Sathe AA, Abdullah KG, McBrayer SK, Adams SH, Brenner AJ，等. 全球DNA甲基化分析揭示了idh突变星形细胞瘤的染色体不稳定性. Acta Neuropathol. Commun. (2022) PMID: 35264242
- Kundu S, Nandhu MS, Longo SL, Longo JA, Rai S, Chin LS, et al. 支架蛋白DLG5通过控制肿瘤干细胞中的Sonic Hedgehog信号传导促进胶质母细胞瘤的生长. Neuro-Oncology (2022) PMID: 34984467
- Lustig SD, Kodali SK, Longo SL, Kundu S, Viapiano MS. Ko143 reverses MDR in glioblastoma via deactivating P-Glycoprotein, sensitizing a resistant phenotype to TMZ treatment. Anticancer Res. (2022) PMID: 35093870
- Lyon JF, Vasudevaraja F, Mirchia K, Walker JM, Corona RJ, Chin LS等. DNA甲基化定位确定idh突变型胶质母细胞瘤的空间进展和分子异质性. Acta Neuropathol. Commun. (2021) PMID: 34193272
- Teixeira SA, Viapiano MS, Andrade AF, Nandhu MS, Pezuk JA, Bidinotto LT等. 碳酸酐酶抑制剂E7070使胶质母细胞瘤细胞对放疗和化疗敏感，并减少肿瘤生长. Mol. Neurobiol. (2021) PMID: 34085182
- Richardson TE, Sathe AA, Xing C, Mirchia K, Viapiano MS, Snuderl M，等. 在idh突变型和idh野生型星形细胞瘤中，染色体不稳定性的分子特征与拷贝数变异模式和患者预后相关. J. Neuropathol. Exp. Neurol. (2021) PMID: 33755138
- von Spreckelsen N, Fadzen CM, Hartrampf N, Ghotmi Y, Wolfe JM, Dubey S，等. 针对胶质母细胞瘤使用一种新的肽特异性布雷维菌素去糖基化异构体. Adv. Ther. (Weinh) (2021) PMID: 33997269
- Galbraith K, Kumar A, Abdullah KG, Walker JM, Adams SH, Prior T等. idh野生型胶质母细胞瘤患者长期存活的分子相关因素. J. Neuropathol. Exp. Neurol. (2020) PMID: 32647886